BIOV Share Price Performance
CHF 22.20
-13.80 (-38.33%)
Price CHF 22.20
Share Pricen/a
Is BioVersys (VTX:BIOV) A Risky Investment?
Sep 27
BioVersys AG Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
BIOV Community Narratives
There are no narratives available yet.
There are no community narratives available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
BioVersys AG Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -3.31
- 100.00%
- -1,478.84%
- 25.8%
About BIOV
- Founded
- 2008
- Employees
- 29
- CEO
- WebsiteView website
BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the treatment of pulmonary tuberculosis; BV200 to treat patients with Atopic dermatitis Staphylococcus aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop novel ansamycin leads from BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
